Evidence-Based Complementary and Alternative Medicine

Review Article

Tianma Gouteng Yin as Adjunctive Treatment for Essential Hypertension: A Systematic Review of Randomized Controlled Trials

Table 6

Analyses of diastolic blood pressure.
Trials MD [95% CI]P Value
TGY plus ACEI versus ACEI   
 modified TGY plus captopril versus captopril1−6.10 [−9.06, −3.14]<0.0001
 TGY plus captopril versus captopril1−5.00 [−5.89, −4.11]<0.00001
 TGY plus captopril versus captopril1−3.69 [−4.44, −2.94]<0.00001
 TGY plus captopril versus captopril1−3.30 [−7.12, 0.52]0.09
 TGY plus captopril versus captopril1−6.28 [−7.55, −5.01]<0.00001
Meta-Analysis5−4.60 [−5.11, −4.09]<0.00001
TGY plus CCB versus CCB   
 modified TGY plus nifedipine sustained release tablets versus nifedipine sustained release tablets1−10.00 [−12.53, −7.47]<0.00001
 modified TGY plus amlodipine besylate versus amlodipine besylate1−8.20 [−8.58, −7.82]<0.00001
 TGY plus nifedipine sustained release tablets versus nifedipine sustained release tablets1−7.34 [−7.73, −6.95]<0.00001
Meta-Analysis3−7.98 [−8.85, −7.12]<0.00001
TGY plus diuretics versus diuretics   
 modified TGY plus hydrochlorothiazide versus hydrochlorothiazide10.44 [−0.52, 1.40]0.37
Meta-Analysis10.44 [−0.52, 1.40]0.37
TGY plus ARB versus ARB   
 TGY plus telmisartan versus telmisartan1−0.80 [−1.57, −0.03]0.04
Meta-Analysis1−0.80 [−1.57, −0.03]0.04
TGY plus “CCB + ACEI” versus “CCB + ACEI”   
 modified TGY plus amlodipine besylate and lisinopril versus amlodipine besylate and lisinopril1−6.87 [−7.60, −6.14]<0.00001
Meta-Analysis1−6.87 [−7.60, −6.14]<0.00001